HR
CRSP icon

Hayden Royal’s CRISPR Therapeutics CRSP Stock Holding History

Hayden Royal’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$280K Sell
3,693
-1,173
-24% -$102K 0.66% 53
2021
Q3 		$545K Sell
4,866
-34
-0.7% -$4.27K 0.89% 26
2021
Q2 		$793K Buy
4,900
+310
+7% +$37.7K 0.44% 65
2021
Q1 		$559K Buy
+4,590
New +$693K 0.32% 75
2020
Q4 		– Sell
-4,045
Closed -$338K – 486
2020
Q3 		$338K Buy
+4,045
New +$359K 0.18% 127

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Hayden Royal's CRSP Position: Q4 2021 in Review

Hayden Royal reduced its CRISPR Therapeutics (CRSP) stake by 24% in Q4 2021, selling an estimated $102K and leaving 3,693 shares worth $280K. The position accounts for 0.66% of the portfolio, ranked #53.

Hayden Royal first reported a position in CRSP in Q3 2020 and has held it in 5 quarters since. The position peaked at $793K in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Hayden Royal held 3,693 shares of CRISPR Therapeutics worth $280K as of Q4 2021.
  • Hayden Royal sold 1,173 CRISPR Therapeutics shares in Q4 2021, an estimated $102K.
  • CRISPR Therapeutics made up 0.66% of Hayden Royal's portfolio in Q4 2021, its #53 holding.
  • Hayden Royal first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 5 quarters since.
  • Hayden Royal's CRISPR Therapeutics position peaked at $793K in Q2 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Hayden Royal's 13F filing for Q4 2021, filed 7 Feb 2022.